|
Product Report
|
 Acute Stroke - TPA spurs infrastructure changes for the better
Stroke is one of the top three leading causes of death worldwide and an area of high unmet needs. TPA is limited to a low number of ischemic stroke patients due to a short therapeutic time window, but it is still the best therapy available. TPA is responsible for major changes and advances in the way stroke patients are cared for, which is expected to evolve further.
|
|
Read more...
|
|
|
Market Report
|
 Analysis of the Pharmaceutical Market to 2012 - Segmented by Drug Target Family
Drug targets are the critical link between drugs and their role in the treatment of medical disorders. By grouping drug targets into key protein families, this report provides a comprehensive analysis of the prescription pharmaceutical market by not just molecule type and therapy area, but also by target family.
|
|
Read more...
|
|
|
Market Report
|
Molecular Targeted Cancer Therapies-Can anything else revolutionize the market?
Approaches to cancer treatment continue to incorporate molecular targeted therapies into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, commercial and strategic challenges are continuing to emerge.
|
|
Read more...
|
|
|
Market Report
|
Cardiovascular market overview - Raft of patent expires threaten blockbusters
Datamonitor expects the cardiovascular market to remain stable with sales only showing negligible growth between 2006 and 2016, below the 3% growth predicted for the SU sold. Generic products will become increasingly important as the majority of products will have lost IP protection, accounting for 30% of cardiovascular sales and 65% of SU sold in 2016.
|
|
Read more...
|
|
|
Market Report
|
HBV drugs market
Fuelled by an increasing disease awareness, the growing use of new, expensive drugs as well as combination therapy, the HBV drugs market, sized at $431m in 2006 across the seven major markets, will nearly triple in size by 2016. Rapid growth until 2011 will slow down in the following years as a result of genericization and the beginning impact of routine HBV vaccination.
|
|
Read more...
|
|
|
Company Report
|
Company Comparator Tool
The Comparator Tool builds from the PharmaVitae profiles of the 50 leading pharma companies. Updated monthly, the tool allows you to compare the 50 players by current and forecast sales to 2012.
|
|
Read more...
|
|
|
Product Report
|
Systemic antifungals
The systemic antifungals market accounts for $3.1bn of the total $41bn anti-infectives market. A wave of new products coinciding with patent expiry of two widely used compounds will shake up the market for systemic infections, further polarizing between winners and losers. Key changes are forcing a rethink of management strategies and clinical trial design.
|
|
Read more...
|
|
|
Company Report
|
Examining Today’s Pharmaceutical Licensing Trends
With Pharma struggling to maintain its pipelines and portfolios with products developed in-house, companies are increasingly turning to licensing. However, the search for late-stage developmental products is becoming tougher and more expensive, and companies are now looking towards licensing earlier-stage compounds.
|
|
Read more...
|
|
|
Market Report
|
Substance Dependence - Part I: Nicotine
The high prevalence of nicotine dependence, strong uptake of Pfizer's Chantix (varenicline), and the launch of new innovative therapies will cause the nicotine dependence prescription drug market to grow to $4.6 billion across the seven major markets by 2016. Innovative therapies are set to offer patients a convenient dosing regimen and thereby carrying the potential for improved compliance.
|
|
Read more...
|
|
|
Market Report
|
Orphan Diseases in CNS - Part I: Huntington's Disease
The current Huntington’s disease market is comprised of off-label prescriptions of psychotropic drugs. In the near term, two pipeline drugs are set to enter the market, demonstrating the viability of this disease as a primary marketing indication. In the longer term, with a strong genetic link and reliable diagnostic test, prophylactic treatment with a disease modifying drug could prove lucrative.
|
|
Read more...
|
|
|
Market Report
|
Head and Neck Cancer
Incidence of head and neck cancer across the seven major markets in 2007 is estimated to total 137,299. Forty percent of these cases present with stage III/IV disease, when patient prognosis is poor. Cisplatin-based therapy continues to dominate treatment, although the toxicities associated with this approach highlights the need for more tolerable alternatives, such as Erbitux.
|
|
Read more...
|
|
|
Market Report
|
Prostate Cancer - Hormone-refractory patients still waiting for treatment breakthroughs
Prostate cancer is one of the four most common tumor types, and is the most common cancer and second most common cause of cancer-related death to affect men. Prostate cancer is curable when localized and frequently responds to treatment at an advanced stage. The rate at which prostate tumors grow varies between patients, with some achieving prolonged survival even with metastatic disease.
|
|
Read more...
|
|
|
Market Report
|
Parkinson's Disease -Evidence of neuroprotection essential to progress treatment dynamics
Parkinson's disease (PD) is a progressive, degenerative condition of the central nervous system that affects the way the brain coordinates body movements, including walking, talking and writing. PD affects less than 1% of the population in the seven major markets (7MM); with patients typically being diagnosed in their early sixties and living for over 18 years after the onset of first symptoms.
|
|
Read more...
|
|
|
Market Report
|
Inflammatory Bowel Disease - Debate over early aggressive treatment continues
Inflammatory bowel disease (IBD) is a chronic inflammatory condition that affects the gastrointestinal tract causing a number of distressing symptoms such as bleeding, diarrhea and abdominal pain. IBD includes key subsets Crohn's disease and ulcerative colitis, both of which can significantly impact on the quality of life of an individual.
|
|
Read more...
|
|
|
Market Report
|
Endometriosis - Scientific clarity will unlock market potential
Endometriosis is a painful, menstrual-related disorder that is thought to affect approximately 10% of the female population of reproductive age. Despite this large patient potential, growth of the endometriosis market has been limited by low levels of investment, poor awareness among physicians and the public, problematic diagnosis, and lack of effective therapies.
|
|
Read more...
|
|
|
Market Report
|
Peripheral artery disease - Poor disease awareness hinders new agents
Peripheral artery disease, sometimes also referred to as peripheral vascular disease, is atherosclerosis in peripheral regions, which can lead to loss of blood flow to the limbs, and can result in loss of life, limb amputation and cardiovascular events. The current pharmacological treatment options are limited, and there are large unmet needs associated with the disease.
|
|
Read more...
|
|
|
Market Report
|
Substance Dependence - Part II: Alcohol
The continued uptake of existing brands and the launch of two opioid antagonists will cause the market to grow at a compound annual growth rate of 13.5% from 2006 to reach $304m across the seven major markets by 2016. The alcohol dependence market requires a paradigm shift away from the public perception that it is a behavioral disorder towards being regarded as a treatable medical condition.
|
|
Read more...
|
|
|
Market Report
|
Orphan Diseases in CNS - Part II: Amyotrophic Lateral Sclerosis
The ALS market was worth $148m in 2006 across the seven major markets. With the only approved treatment for ALS, Sanofi-Aventis's Rilutek (riluzole), facing generic incursion in 2012-13, future growth in this market is dependent on the success of pipeline drugs.
|
|
Read more...
|
|
Farmavita.Net Journal 
